image
21369040
One of the buildings of the headquarters of Gilead Sciences, Inc. in Foster City, CA, on April 30, 2020. Its drug, Remdesivir, may be near regulatory authorization in the U.S. as a COVID-19 treatment following early data readouts for a pair of clinical trial. (KEYSTONE/LAIF/Frederic Neema)
Instructions
COPYRIGHTPFLICHTIG _(86.13 MB vorhanden)_
Licence
Rights Managed
Date de création
20200430
Lieu
USA VEREINIGTE STAATEN AMERIKA
Credit
KEYSTONE
Source
LAIF
Byline
FREDERIC NEEMA
Taille
4480 x 6720 px
Type de fichier
JPEG